A Study of mRNA Vaccines AK154 Monotherapy or in Combination With AK104/AK112,and Sequential mFOLFIRINOX in Surgically Resected PDAC

Inclusion Criteria: * Voluntarily signed the informed consent form and complied with protocols requirements * Patients with radiographically resectable primary pancreatic tumors * Histopathology or cytology confirmed resected PDAC with macroscopic complete resection (R0 and R1) * Pancreatic cancer surgical staging per AJCC 8th edition staging: T 1-3, N0-2, M0 * ECOG 0 or 1 * Life expectancy ≥ 6 months * Surgical complications have recovered, * Adequate organ function * Patients with fertility are willing to use an adequate method of contraception. Exclusion Criteria: * The presence of other pathologic types * Participating in another clinical study * Have received treatment for pancreatic cancer, including chemotherapy, radiation therapy, targeted therapy, immunotherapy,etc * Plan to receive a live-attenuated vaccine within 28 days prior to initiation of study treatment or during the study treatment or within 90 days after the end of study treatment * Severe infection occurs within 4 weeks prior to the first dose * Requiring systemic therapy with glucocorticoids or other immunosuppressive drugs within 14 days prior to initial administration. * Acute pancreatitis or subclinical pancreatitis * Active autoimmune disease * Allergic to immunotherapies and related drugs * History of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation. * Splenectomy history * Active tuberculosis * Known or highly suspected history of interstitial pneumonia. * Clinically significant liver disease * Uncontrolled or severe cardiovascular disease. * Severe bleeding tendency or history of coagulopathy * Active malignancy within the last 3 years * Active syphilis infection * Any other situations that are not suitable for inclusion in this study judged by investigator.